157 related articles for article (PubMed ID: 27659742)
21. Monogenetic causes of chilblains, panniculitis and vasculopathy: the Type I interferonopathies.
Papa R; Volpi S; Gattorno M
G Ital Dermatol Venereol; 2020 Oct; 155(5):590-598. PubMed ID: 32618445
[TBL] [Abstract][Full Text] [Related]
22. The important roles of type I interferon and interferon-inducible genes in systemic lupus erythematosus.
Luo S; Wang Y; Zhao M; Lu Q
Int Immunopharmacol; 2016 Nov; 40():542-549. PubMed ID: 27769023
[TBL] [Abstract][Full Text] [Related]
23. Expression of Long Interspersed Nuclear Element 1 Retroelements and Induction of Type I Interferon in Patients With Systemic Autoimmune Disease.
Mavragani CP; Sagalovskiy I; Guo Q; Nezos A; Kapsogeorgou EK; Lu P; Liang Zhou J; Kirou KA; Seshan SV; Moutsopoulos HM; Crow MK
Arthritis Rheumatol; 2016 Nov; 68(11):2686-2696. PubMed ID: 27338297
[TBL] [Abstract][Full Text] [Related]
24. The type I interferons: Basic concepts and clinical relevance in immune-mediated inflammatory diseases.
López de Padilla CM; Niewold TB
Gene; 2016 Jan; 576(1 Pt 1):14-21. PubMed ID: 26410416
[TBL] [Abstract][Full Text] [Related]
25. Type I interferon-mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview.
Rodero MP; Crow YJ
J Exp Med; 2016 Nov; 213(12):2527-2538. PubMed ID: 27821552
[TBL] [Abstract][Full Text] [Related]
26. RIG-I-like receptors and autoimmune diseases.
Kato H; Fujita T
Curr Opin Immunol; 2015 Dec; 37():40-5. PubMed ID: 26530735
[TBL] [Abstract][Full Text] [Related]
27. Spondyloenchondrodysplasia Due to Mutations in ACP5: A Comprehensive Survey.
Briggs TA; Rice GI; Adib N; Ades L; Barete S; Baskar K; Baudouin V; Cebeci AN; Clapuyt P; Coman D; De Somer L; Finezilber Y; Frydman M; Guven A; Heritier S; Karall D; Kulkarni ML; Lebon P; Levitt D; Le Merrer M; Linglart A; Livingston JH; Navarro V; Okenfuss E; Puel A; Revencu N; Scholl-Bürgi S; Vivarelli M; Wouters C; Bader-Meunier B; Crow YJ
J Clin Immunol; 2016 Apr; 36(3):220-34. PubMed ID: 26951490
[TBL] [Abstract][Full Text] [Related]
28. Aicardi-Goutières syndrome and the type I interferonopathies.
Crow YJ; Manel N
Nat Rev Immunol; 2015 Jul; 15(7):429-40. PubMed ID: 26052098
[TBL] [Abstract][Full Text] [Related]
29. Targeting of type I interferon in systemic autoimmune diseases.
Crow MK; Olferiev M; Kirou KA
Transl Res; 2015 Feb; 165(2):296-305. PubMed ID: 25468480
[TBL] [Abstract][Full Text] [Related]
30. Type I interferon detection in autoimmune diseases: challenges and clinical applications.
Papadopoulos VE; Skarlis C; Evangelopoulos ME; Mavragani CP
Expert Rev Clin Immunol; 2021 Aug; 17(8):883-903. PubMed ID: 34096436
[TBL] [Abstract][Full Text] [Related]
31. An Update on Autoinflammatory Diseases: Interferonopathies.
Davidson S; Steiner A; Harapas CR; Masters SL
Curr Rheumatol Rep; 2018 May; 20(7):38. PubMed ID: 29846818
[TBL] [Abstract][Full Text] [Related]
32. Development of a Validated Interferon Score Using NanoString Technology.
Kim H; de Jesus AA; Brooks SR; Liu Y; Huang Y; VanTries R; Montealegre Sanchez GA; Rotman Y; Gadina M; Goldbach-Mansky R
J Interferon Cytokine Res; 2018 Apr; 38(4):171-185. PubMed ID: 29638206
[TBL] [Abstract][Full Text] [Related]
33. Systemic Lupus Erythematosus--A Disease with A Dysregulated Type I Interferon System.
Hagberg N; Rönnblom L
Scand J Immunol; 2015 Sep; 82(3):199-207. PubMed ID: 26099519
[TBL] [Abstract][Full Text] [Related]
34. The murine cytomegalovirus M35 protein antagonizes type I IFN induction downstream of pattern recognition receptors by targeting NF-κB mediated transcription.
Chan B; Gonçalves Magalhães V; Lemmermann NAW; Juranić Lisnić V; Stempel M; Bussey KA; Reimer E; Podlech J; Lienenklaus S; Reddehase MJ; Jonjić S; Brinkmann MM
PLoS Pathog; 2017 May; 13(5):e1006382. PubMed ID: 28542326
[TBL] [Abstract][Full Text] [Related]
35. Type I interferon pathway in CNS homeostasis and neurological disorders.
Blank T; Prinz M
Glia; 2017 Sep; 65(9):1397-1406. PubMed ID: 28519900
[TBL] [Abstract][Full Text] [Related]
36. Stimulator of Interferon Genes-Associated Vasculopathy With Onset in Infancy: A Mimic of Childhood Granulomatosis With Polyangiitis.
Munoz J; Rodière M; Jeremiah N; Rieux-Laucat F; Oojageer A; Rice GI; Rozenberg F; Crow YJ; Bessis D
JAMA Dermatol; 2015 Aug; 151(8):872-7. PubMed ID: 25992765
[TBL] [Abstract][Full Text] [Related]
37. Breaking down the cellular responses to type I interferon neurotoxicity in the brain.
Viengkhou B; Hofer MJ
Front Immunol; 2023; 14():1110593. PubMed ID: 36817430
[TBL] [Abstract][Full Text] [Related]
38. Familial Chilblain Lupus - What Can We Learn from Type I Interferonopathies?
Fiehn C
Curr Rheumatol Rep; 2017 Aug; 19(10):61. PubMed ID: 28844088
[TBL] [Abstract][Full Text] [Related]
39. Type I interferon in neurological disease-the devil from within.
Hofer MJ; Campbell IL
Cytokine Growth Factor Rev; 2013 Jun; 24(3):257-67. PubMed ID: 23548179
[TBL] [Abstract][Full Text] [Related]
40. Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon β in dermatomyositis.
Huard C; Gullà SV; Bennett DV; Coyle AJ; Vleugels RA; Greenberg SA
Br J Dermatol; 2017 May; 176(5):1224-1230. PubMed ID: 27564228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
